Abdominal Radiology

, Volume 43, Issue 5, pp 1237–1244 | Cite as

Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer

  • Elmira Hassanzadeh
  • Francesco AlessandrinoEmail author
  • Olutayo I. Olubiyi
  • Daniel I. Glazer
  • Robert V. Mulkern
  • Andriy Fedorov
  • Clare M. Tempany
  • Fiona M. Fennessy



To compare diagnostic performance of PI-RADSv2 with ADC parameters to identify clinically significant prostate cancer (csPC) and to determine the impact of csPC definitions on diagnostic performance of ADC and PI-RADSv2.


We retrospectively identified treatment-naïve pathology-proven peripheral zone PC patients who underwent 3T prostate MRI, using high b-value diffusion-weighted imaging from 2011 to 2015. Using 3D slicer, areas of suspected tumor (T) and normal tissue (N) on ADC (b = 0, 1400) were outlined volumetrically. Mean ADCT, mean ADCN, ADCratio (ADCT/ADCN) were calculated. PI-RADSv2 was assigned. Three csPC definitions were used: (A) Gleason score (GS) ≥ 4 + 3; (B) GS ≥ 3 + 4; (C) MRI-based tumor volume >0.5 cc. Performances of ADC parameters and PI-RADSv2 in identifying csPC were measured using nonparametric comparison of receiver operating characteristic curves using the area under the curve (AUC).


Eighty five cases met eligibility requirements. Diagnostic performances (AUC) in identifying csPC using three definitions were: (A) ADCT (0.83) was higher than PI-RADSv2 (0.65, p = 0.006); (B) ADCT (0.86) was higher than ADCratio (0.68, p < 0.001), and PI-RADSv2 (0.70, p = 0.04); (C) PI-RADSv2 (0.73) performed better than ADCratio (0.56, p = 0.02). ADCT performance was higher when csPC was defined by A or B versus C (p = 0.038 and p = 0.01, respectively). ADCratio performed better when csPC was defined by A versus C (p = 0.01). PI-RADSv2 performance was not affected by csPC definition.


When csPC was defined by GS, ADC parameters provided better csPC discrimination than PI-RADSv2, with ADCT providing best result. When csPC was defined by MRI-calculated volume, PI-RADSv2 provided better discrimination than ADCratio. csPC definition did not affect PI-RADSv2 diagnostic performance.


Prostate cancer Magnetic resonance imaging Diffusion-weighted imaging Apparent diffusion coefficient PI-RADSv2 Gleason score 



The authors thank all the technologists, especially Nancy Trane, RT for her dedication.

Compliance with ethical standards


This study was funded by National Institute of Health – National Cancer Institute: U01 CA151261 (Fiona M Fennessy, Andriy Fedorov); R25 CA089017 (Fiona M Fennessy, Daniel I Glazer, Clare M Tempany); NIH P41 EB 015898 (Clare M Tempany, Fiona M Fennessy, Andriy Fedorov).

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.


  1. 1.
    Miller KD, Siegel RL, Lin CC, et al. (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin 66(4):271–289CrossRefPubMedGoogle Scholar
  2. 2.
    Loeb S, Bjurlin MA, Nicholson J, et al. (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Etzioni R, Penson DF, Legler JM, et al. (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990CrossRefPubMedGoogle Scholar
  4. 4.
    Ahmed HU, Hu Y, Carter T, et al. (2011) Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 186(2):458–464CrossRefPubMedGoogle Scholar
  5. 5.
    Rasiah KK, Stricker PD, Haynes A-M, et al. (2003) Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 98(12):2560–2565CrossRefPubMedGoogle Scholar
  6. 6.
    Wolters T, Roobol MJ, van Leeuwen PJ, et al. (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185(1):121–125CrossRefPubMedGoogle Scholar
  7. 7.
    Kumar V, Jagannathan NR, Kumar R, et al. (2007) Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed 20(5):505–511CrossRefPubMedGoogle Scholar
  8. 8.
    Woo S, Kim SY, Cho JY, et al. (2016) Preoperative evaluation of prostate cancer aggressiveness: using ADC and ADC ratio in determining Gleason score. AJR 207(1):114–120CrossRefPubMedGoogle Scholar
  9. 9.
    Hambrock T, Somford DM, Huisman HJ, et al. (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461CrossRefPubMedGoogle Scholar
  10. 10.
    Vargas HA, Akin O, Franiel T, et al. (2011) Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259(3):775–784CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Metens T, Miranda D, Absil J, et al. (2012) What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol 22(3):703–709CrossRefPubMedGoogle Scholar
  12. 12.
    Kim CK, Park BK (2010) Kim B (2010) High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. AJR 194(1):W33–W37CrossRefPubMedGoogle Scholar
  13. 13.
    Weinreb JC, Barentsz JO, Choyke PL, et al. (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40CrossRefPubMedGoogle Scholar
  14. 14.
    Bratan F, Niaf E, Melodelima C, et al. (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23(7):2019–2029CrossRefPubMedGoogle Scholar
  15. 15.
    Jambor I, Boström PJ, Taimen P, et al. (2017) Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging. doi: 10.1002/jmri.25641 Google Scholar
  16. 16.
    Ahmed HU, El-Shater Bosaily A, Brown LC, et al. (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822CrossRefPubMedGoogle Scholar
  17. 17.
    Kozlowski P, Chang SD, Goldenberg SL (2008) Diffusion-weighted MRI in prostate cancer—comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging 26(1):72–76CrossRefPubMedGoogle Scholar
  18. 18.
    Barentsz JO, Richenberg J, Clements R, et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    McNeal JE, Redwine EA, Freiha FS, et al. (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12(12):897–906CrossRefPubMedGoogle Scholar
  20. 20.
    Vargas HA, Hötker AM, Goldman DA, et al. (2016) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 26(6):1606–1612CrossRefPubMedGoogle Scholar
  21. 21.
    Hegde JV, Mulkern RV, Panych LP, et al. (2013) Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 37(5):1035–1054CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Srigley JR, Humphrey PA, Amin MB, et al. (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133(10):1568–1576PubMedGoogle Scholar
  23. 23.
    Fedorov A, Beichel R, Kalpathy-Cramer J, et al. (2012) 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 30(9):1323–1341CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Fedorov A, Vangel MG, Tempany CM, Fennessy FM (2017) Multiparametric magnetic resonance imaging of the prostate: repeatability of volume and apparent diffusion coefficient quantification. Investig Radiol 52(9):538–546CrossRefGoogle Scholar
  25. 25.
    DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMedGoogle Scholar
  26. 26.
    Stensland KD, Coutinho K, Hobbs AR, et al. (2016) Are magnetic resonance imaging undetectable prostate tumours clinically significant? Results of histopathological analyses. Arab J Urol 14(4):256–261CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Truong M, Hollenberg G, Weinberg E, et al. (2017) Impact of Gleason subtype on prostate cancer detection using multiparametric MRI: correlation with final histopathology. J Urol. doi: 10.1016/j.juro.2017.01.077 Google Scholar
  28. 28.
    Turkbey B, Mani H, Aras O, et al. (2012) Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 188(4):1157–1163CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Priester A, Natarajan S, Khoshnoodi P, et al. (2017) Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J Urol 197(2):320–326CrossRefPubMedGoogle Scholar
  30. 30.
    Zhao C, Gao G, Fang D, et al. (2016) The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS version 2 in the diagnosis of clinically significant prostate cancer. Clin Imaging 40(5):885–888CrossRefPubMedGoogle Scholar
  31. 31.
    Lin WC, Westphalen AC, Silva GE, et al. (2016) Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer. Abdom Radiol (NY) 41(11):2209–2217CrossRefGoogle Scholar
  32. 32.
    Glazer DI, Hassanzadeh E, Fedorov A, et al. (2017) Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (NY) 42(3):918–925CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Donati OF, Mazaheri Y, Afaq A, et al. (2014) Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 271(1):143–152CrossRefPubMedGoogle Scholar
  34. 34.
    Lebovici A, Sfrangeu SA, Feier D, et al. (2014) Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging 14:15CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Boesen L, Chabanova E, Løgager V, et al. (2015) Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology. J Magn Reson Imaging 42(2):446–453CrossRefPubMedGoogle Scholar
  36. 36.
    Jones AC, Antillon KS, Jenkins SM, et al. (2015) Prostate field cancerization: deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. PLoS One 10(3):e0119314CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Mulkern RV, Barnes AS, Haker SJ, et al. (2006) Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 24(5):563–568CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Agarwal HK, Mertan FV, Sankineni S, et al. (2017) Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. J Magn Reson Imaging 45(1):125–131CrossRefPubMedGoogle Scholar
  39. 39.
    Ukimura O, Coleman JA, de la Taille A, et al. (2013) Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 63(2):214–230CrossRefPubMedGoogle Scholar
  40. 40.
    Purysko AS, Bittencourt LK, Bullen JA, et al. (2017) Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric MRI of the prostate. AJR 209(2):339–349CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Elmira Hassanzadeh
    • 1
    • 2
  • Francesco Alessandrino
    • 1
    • 3
    Email author
  • Olutayo I. Olubiyi
    • 1
    • 4
  • Daniel I. Glazer
    • 1
  • Robert V. Mulkern
    • 5
  • Andriy Fedorov
    • 1
  • Clare M. Tempany
    • 1
  • Fiona M. Fennessy
    • 1
    • 3
  1. 1.Department of Radiology, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Department of SurgeryUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Department of ImagingDana Farber Cancer InstituteBostonUSA
  4. 4.Department of RadiologyMercy Catholic Medical CenterDarbyUSA
  5. 5.Department of Radiology, Boston Children’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations